Apoptotic Donor Leukocytes Limit Mixed-Chimerism Induced by CD40-CD154 Blockade in Allogeneic Bone Marrow Transplantation Jian-ming Li, John Gorechlad,

Slides:

Advertisements

Similar presentations

Erik Ames, Salif Harouna, Colin Meyer, Lisbeth A. Welniak, William J

Advertisements

Joseph H. Chewning, Weiwei Zhang, David A. Randolph, C

Critical Roles of Lysosomal Acid Lipase in Myelopoiesis

Host-Derived CD8+ Dendritic Cells Protect Against Acute Graft-versus-Host Disease after Experimental Allogeneic Bone Marrow Transplantation Michael Weber,

William H. D. Hallett, Weiqing Jing, William R. Drobyski, Bryon D

Depletion of Naïve Lymphocytes with Fas Ligand Ex Vivo Prevents Graft-versus-Host Disease without Impairing T Cell Support of Engraftment or Graft-versus-Tumor.

The Fifth Epidermal Growth Factor–like Region of Thrombomodulin Alleviates Murine Graft-versus-Host Disease in a G-Protein Coupled Receptor 15 Dependent.

Influence of Donor Microbiota on the Severity of Experimental Graft-versus-Host- Disease Isao Tawara, Chen Liu, Hiroya Tamaki, Tomomi Toubai, Yaping Sun,

Stromal-Derived Factor-1α and Interleukin-7 Treatment Improves Homeostatic Proliferation of Naïve CD4+ T Cells after Allogeneic Stem Cell Transplantation

Extracorporeal Photopheresis Attenuates Murine Graft-versus-Host Disease via Bone Marrow–Derived Interleukin-10 and Preserves Responses to Dendritic Cell.

IL-2–Targeted Therapy Ameliorates the Severity of Graft-versus-Host Disease: Ex Vivo Selective Depletion of Host-Reactive T Cells and In Vivo Therapy

Host conditioning with total lymphoid irradiation and antithymocyte globulin prevents graft-versus-host disease: the role of CD1-reactive natural killer.

Identification of Stem Cell Transcriptional Programs Normally Expressed in Embryonic and Neural Stem Cells in Alloreactive CD8+ T Cells Mediating Graft-versus-Host.

Juyang Kim, Wongyoung Kim, Hyun J. Kim, Sohye Park, Hyun-A

Induction of Immunity to Neuroblastoma Early after Syngeneic Hematopoietic Stem Cell Transplantation Using a Novel Mouse Tumor Vaccine Weiqing Jing,

Ping Zhang, Jieying Wu, Divino Deoliveira, Nelson J. Chao, Benny J

by Silke Huber, Reinhard Hoffmann, Femke Muskens, and David Voehringer

William H. D. Hallett, Weiqing Jing, William R. Drobyski, Bryon D

Prevention of Acute Graft-versus-Host Disease in a Xenogeneic SCID Mouse Model by the Humanized Anti-CD74 Antagonistic Antibody Milatuzumab Xiaochuan.

Preventive Azithromycin Treatment Reduces Noninfectious Lung Injury and Acute Graft- versus-Host Disease in a Murine Model of Allogeneic Hematopoietic.

Ex Vivo Rapamycin Generates Th1/Tc1 or Th2/Tc2 Effector T Cells With Enhanced In Vivo Function and Differential Sensitivity to Post-transplant Rapamycin.

LBH589 Enhances T Cell Activation In Vivo and Accelerates Graft-versus-Host Disease in Mice Dapeng Wang, Cristina Iclozan, Chen Liu, Changqing Xia, Claudio.

Cytosine-Phosphorothionate-Guanine Oligodeoxynucleotides Exacerbates Hemophagocytosis by Inducing Tumor Necrosis Factor–Alpha Production in Mice after.

Altered Homeostasis of CD4+ Memory T Cells in Allogeneic Hematopoietic Stem Cell Transplant Recipients: Chronic Graft-versus-Host Disease Enhances T Cell.

A Non-Leaky Artemis-Deficient Mouse That Accurately Models the Human Severe Combined Immune Deficiency Phenotype, Including Resistance to Hematopoietic.

Blocking LFA-1 Activation with Lovastatin Prevents Graft-versus-Host Disease in Mouse Bone Marrow Transplantation Yang Wang, Dan Li, Dan Jones, Roland.

Growth and Differentiation Advantages of CD4+OX40+ T Cells from Allogeneic Hematopoietic Stem Cell Transplantation Recipients Takero Shindo, Takayuki.

IL-17 Gene Ablation Does Not Impact Treg-Mediated Suppression of Graft-Versus-Host Disease after Bone Marrow Transplantation Lucrezia Colonna, Mareike.

The Synthetic Triterpenoid, CDDO, Suppresses Alloreactive T Cell Responses and Reduces Murine Early Acute Graft-versus-Host Disease Mortality Kai Sun,

Evelyn C. Nieves, Tomomi Toubai, Daniel C

Pharmacologic Expansion of Donor-Derived, Naturally Occurring CD4+Foxp3+ Regulatory T Cells Reduces Acute Graft-versus-Host Disease Lethality Without.

FTY720 Markedly Increases Alloengraftment but Does Not Eliminate Host Anti-Donor T Cells that Cause Graft Rejection on Its Withdrawal Patricia A. Taylor,

Volume 25, Issue 3, Pages (March 2017)

Double Haploidentical Hematopoietic Stem Cell Transplantation Results in Successful Engraftment of Bone Marrow from Both Donors without Graft-versus-Host.

Activated Allogeneic NK Cells as Suppressors of Alloreactive Responses

An Essential Role for IFN-γ in Regulation of Alloreactive CD8 T Cells Following Allogeneic Hematopoietic Cell Transplantation Wannee Asavaroengchai,

Survival and Function of MiHA Epitope-Specific Host CD8 TM Cells Following Ablative Conditioning and HCT Alwi M. Shatry, Derry C. Roopenian, Robert B.

Depletion of Host CCR7+ Dendritic Cells Prevented Donor T Cell Tissue Tropism in Anti- CD3–Conditioned Recipients Wei He, Jeremy J. Racine, Heather F.

Volume 135, Issue 3, Pages (September 2008)

The Pentostatin Plus Cyclophosphamide Nonmyeloablative Regimen Induces Durable Host T Cell Functional Deficits and Prevents Murine Marrow Allograft Rejection

Enrichment of IL-12–Producing Plasmacytoid Dendritic Cells in Donor Bone Marrow Grafts Enhances Graft-versus-Leukemia Activity in Allogeneic Hematopoietic.

Essential Role of Interleukin-12/23p40 in the Development of Graft-versus-Host Disease in Mice Yongxia Wu, David Bastian, Steven Schutt, Hung Nguyen,

Hydrodynamic Delivery of Human IL-15 cDNA Increases Murine Natural Killer Cell Recovery after Syngeneic Bone Marrow Transplantation Isabel Barao, Maite.

Distinct phases in recovery of reconstituted innate cellular-mediated immunity after murine syngeneic bone marrow transplantation Jeffery J. Auletta,

Murine Bone Marrow Stromal Progenitor Cells Elicit an In Vivo Cellular and Humoral Alloimmune Response Andrea T. Badillo, Kirstin J. Beggs, Elisabeth.

Augmentation of antitumor immune responses after adoptive transfer of bone marrow derived from donors immunized with tumor lysate-pulsed dendritic cells

The Triterpenoid CDDO-Me Delays Murine Acute Graft-versus-Host Disease with the Preservation of Graft-versus-Tumor Effects after Allogeneic Bone Marrow.

Host Basophils Are Dispensable for Induction of Donor T Helper 2 Cell Differentiation and Severity of Experimental Graft-versus-Host Disease Isao Tawara,

Effector Cells Derived from Host CD8 Memory T Cells Mediate Rapid Resistance against Minor Histocompatibility Antigen-Mismatched Allogeneic Marrow Grafts.

A Radio-Resistant Perforin-Expressing Lymphoid Population Controls Allogeneic T Cell Engraftment, Activation, and Onset of Graft-versus-Host Disease in.

Atul Sathe, Sterling B. Ortega, Dorothy I. Mundy, Robert H

Dynamic Change and Impact of Myeloid-Derived Suppressor Cells in Allogeneic Bone Marrow Transplantation in Mice Dapeng Wang, Yu Yu, Kelley Haarberg,

A CD4 Domain 1 CC′ Loop Peptide Analogue Enhances Engraftment in a Murine Model of Bone Marrow Transplantation with Sublethal Conditioning Gabor Varadi,

Amotosalen-treated donor T cells have polyclonal antigen-specific long-term function without graft-versus-host disease after allogeneic bone marrow transplantation

Elevation of Intracellular Cyclic AMP in Alloreactive CD4+ T Cells Induces Alloantigen- Specific Tolerance That Can Prevent GVHD Lethality In Vivo Matthew.

Tracking ex vivo-expanded CD4+CD25+ and CD8+CD25+ regulatory T cells after infusion to prevent donor lymphocyte infusion-induced lethal acute graft-versus-host.

In Situ Activation and Expansion of Host Tregs: A New Approach to Enhance Donor Chimerism and Stable Engraftment in Major Histocompatibility Complex-Matched.

B7.2−/− Mature Dendritic Cells Generate T-Helper 2 and Regulatory T Donor Cells in Fetal Mice after In Utero Allogeneic Bone Marrow Transplantation Swati.

Volume 9, Issue 2, Pages (August 2011)

CpG-Induced Myeloid CD11b+Gr-1+ Cells Efficiently Suppress T Cell–Mediated Immunoreactivity and Graft-Versus-Host Disease in a Murine Model of Allogeneic.

CD25 expression distinguishes functionally distinct alloreactive CD4+ CD134+ (OX40+) T-cell subsets in acute graft-versus-host disease Philip R Streeter,

Cytokines and cytotoxic pathways in engraftment resistance to purified allogeneic hematopoietic stem cells Christian Scheffold, Yolanda C. Scheffold,

Donor antigen-presenting cells regulate T-cell expansion and antitumor activity after allogeneic bone marrow transplantation Jian-Ming Li, Edmund K.

Brile Chung, Eric Dudl, Akira Toyama, Lora Barsky, Kenneth I. Weinberg

Early Vaccination with Tumor Lysate-Pulsed Dendritic Cells after Allogeneic Bone Marrow Transplantation Has Antitumor Effects Jeffrey S. Moyer, Gabriel.

Lack of correlation between an assay used to determine early marrow allograft rejection and long-term chimerism after murine allogeneic bone marrow transplantation:

Volume 29, Issue 4, Pages (October 2008)

Raimon Duran-Struuck, Isao Tawara, Kathi Lowler, Shawn G

Sibylle von Vietinghoff, Hui Ouyang, Klaus Ley Kidney International

Roles of CD28, CTLA4, and Inducible Costimulator in Acute Graft-versus-Host Disease in Mice Jun Li, Kenrick Semple, Woong-Kyung Suh, Chen Liu, Fangping.

Presentation transcript:

Apoptotic Donor Leukocytes Limit Mixed-Chimerism Induced by CD40-CD154 Blockade in Allogeneic Bone Marrow Transplantation Jian-ming Li, John Gorechlad, Christian P. Larsen, Edmund K. Waller Biology of Blood and Marrow Transplantation Volume 12, Issue 12, Pages 1239-1249 (December 2006) DOI: 10.1016/j.bbmt.2006.08.038 Copyright © 2006 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 1 Untreated splenocytes promoted donor engraftment. A, Experimental design. B10.BR (H-2kk, CD45.2, CD90.2) mice received intravenously 500 μg anti-CD154 mAb on days −7, −6, −4, and −2 before transplantation and on days 0 and 6 after transplantation. Busulfan 20 mg/kg was given intraperitoneally on day −1. In addition, 3 × 107 C57BL/6 congenic (CD45.1, H-2kb, CD90.1) splenocytes were infused on day −6 and 2 × 107 C57BL/6 congenic (CD45.1, H-2kb, CD90.2) TCD-BM was administered on day 0 intravenously. The transplantation experiment was repeated 3 times and 5 mice underwent transplantation for each condition in each experiment. Peripheral blood was collected from the recipients at days 30 and 60 after transplantation. Peripheral blood lymphocytes were stained with CD45.1, CD45.2, CD90.1, and CD90.2 and analyzed by flow cytometry. *P < .05 versus TCD-BM alone. B, Illustration of donor and host leukocytes and T cell gate. C, Donor cell percentage. Biology of Blood and Marrow Transplantation 2006 12, 1239-1249DOI: (10.1016/j.bbmt.2006.08.038) Copyright © 2006 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 2 Treated splenocytes had no donor engraft promotion. The experimental design was similar to that shown in Figure 1, except donor cells included 3 × 107 C57BL/6 congenic (CD45.1, H-2kb, CD90.1) untreated splenocytes, psoralen/UV-A treatment (P-SP), or after 24 hour of culture in media containing fludarabine (F-SP) were infused on day −6 and 2 × 107 C57BL/6 congenic (CD45.1, H-2kb, CD90.2) TCD-BM was administered on day 0. Peripheral blood was collected from the recipients at days 30, 130, 190, and 250 after transplantation. Five mice underwent transplantation for each condition, and the experiment was repeated twice. Peripheral blood lymphocytes were stained with CD45.1, CD45.2, CD90.1, and CD90.2 and analyzed by flow cytometry. The percentage of donor cells is shown. *P < .05 versus TCD-BM alone. Biology of Blood and Marrow Transplantation 2006 12, 1239-1249DOI: (10.1016/j.bbmt.2006.08.038) Copyright © 2006 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 3 CD11b+-enriched splenocytes administered on day −6 before transplantation led to the highest level of donor engraftment. The experimental design was similar to that shown in Figure 1, except donor cells included 3 × 107 C57BL/6 congenic (CD45.2, H-2kb, CD90.1) untreated splenocytes, or manipulated splenocytes (CD3+, CD3−, CD11b+, and CD11b−) were infused on day −6, and 2 × 107 C57BL/6 congenic (CD45.1, H-2kb, CD90.2) TCD-BM was administered on day 0 intravenously. Peripheral blood was collected from the recipients on days 20 and 90 after transplantation. Five mice underwent transplantation for each condition in each experiment, and the transplantation experiment was repeated twice. Peripheral blood lymphocytes were stained with CD3, CD11b, CD45.2, and H-2Kb and analyzed by flow cytometry. A, Dot plot of peripheral blood cells. Upper panel, Phenotyped peripheral blood cells after transplantation. Left and right panels, Phenotyped recipient/donor population cells after transplantation. B, Percentage of donor BM-derived cells. *P < .05, comparisons between groups. C, Percentages of recipient and donor BM-derived CD3 T cells and CD11b myeloid cells after transplantation in different groups. Biology of Blood and Marrow Transplantation 2006 12, 1239-1249DOI: (10.1016/j.bbmt.2006.08.038) Copyright © 2006 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 4 Apoptotic splenocytes diminished donor engraftment. The experimental design was similar to that shown in Figure 1, except donor cells included 3 × 107 C57BL/6 congenic (CD45.1, H-2kb, CD90.1) untreated splenocytes, 7.5-, 15-, or 30-Gy irradiated splenocytes (I-SP) were infused on day −6 and 2 × 107 C57BL/6 congenic (CD45.1, H-2kb, CD90.2) TCD-BM was administered on day 0 intravenously. The transplantation experiment was repeated 3 times and 5 mice, excepting 10 mice in recipients of irradiated donor splenocytes, underwent transplantation for each condition in each experiment. Peripheral blood was collected from the recipients at days 30, 130, and 160 after transplantation. Peripheral blood lymphocytes were stained with CD45.1, CD45.2, CD90.1, and CD90.2 and analyzed by flow cytometry. *P < .05 versus TCD-BM alone. Donor cell percentage is presented. Biology of Blood and Marrow Transplantation 2006 12, 1239-1249DOI: (10.1016/j.bbmt.2006.08.038) Copyright © 2006 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 5 Proliferation induced by viable alloantigen, but not apoptotic alloantigen, was suppressed by anti-CD154 mAb. A, Percentage of Annexin V+ apoptotic cells 4 hours after exposure of splenocytes to 0, 7.5, 15, or 30 Gy of irradiation (I-SP). B, Representative CFSE proliferation histograms of H-2Kb T cells (2 × 105) 72 hours after initiation of MLR with nonirradiated or 30-Gy irradiated H-2Kk stimulator splenocytes in the presence or absence of anti-CD154 mAb. Numbers represent percentages of cells in each division peak. Six or 8 replicates were set up per group, and experiments were repeated twice. The divided T cell precursor fractions in the different MLR conditions were calculated as 0-Gy stimulators without anti-CD154 (0.5 ± 0.1), 0-Gy stimulators with anti-CD154 (0.3 ± 0.04), 30-Gy stimulators without anti-CD154 (0.45 ± 0.08), and 30-Gy stimulators with anti-CD154 (0.45 ± 0.09). C, Enzyme-linked immunosorbent assay determinations of IFN-γ, TNF-α, and IL-10 concentrations in supernatants from 72-hour MLR from B. The cytokine concentrations were compared between MLRs that received anti-CD154 (solid bars) and MLRs without anti-CD154 (open bars), *P < .05. Biology of Blood and Marrow Transplantation 2006 12, 1239-1249DOI: (10.1016/j.bbmt.2006.08.038) Copyright © 2006 American Society for Blood and Marrow Transplantation Terms and Conditions